Profile Study of Drug and Supplement Use in COVID-19  January 2022 – December 2022 at the Purworejo Regional Hospital

Ayu Nissa Ainni; Chondrosuro Miyarso; Anwar Sodik; Vinca Elyana Purwanti

doi:10.54209/jurnaleduhealth.v14i3.2518

Authors

Ayu Nissa Ainni Program Studi S1 Farmasi Fakultas Ilmu Kesehatan Universitas Muhammadiyah Gombong
Chondrosuro Miyarso Program Studi S1 Farmasi Fakultas Ilmu Kesehatan Universitas Muhammadiyah Gombong
Anwar Sodik Program Studi S1 Farmasi Fakultas Ilmu Kesehatan Universitas Muhammadiyah Gombong
Vinca Elyana Purwanti Program Studi S1 Farmasi Fakultas Ilmu Kesehatan Universitas Muhammadiyah Gombong

DOI:

https://doi.org/10.54209/jurnaleduhealth.v14i3.2518

Keywords:

Drug Profile, Suplement, COVID-19 patient

Abstract

Coronavirus 19 or known as COVID-19 is a disease caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus. Treatment for COVID-19 is still in the form of supportive therapy and symptomatic therapy. In addition, the use of drugs is more on the complaints felt by patients and comorbidities. This study aims to look at the profile of drug and supplement use in COVID-19 patients at Hospital X, Purworejo area. This research is included in descriptive research with retrospective data collection. The data for this study consisted of all prescriptions and medical records of COVID-19 patients for the January-December 2022 period who met the inclusion criteria. The results of collecting data on COVID-19 patients who met the inclusion criteria obtained 100 medical record data. The characteristics of COVID-19 patients at Hospital X Purworejo area are dominated by men, in the age group over 65 years, with patients who have a history of comorbid pneumonia, and length of stay of more than 5 days. The results of the treatment profile of COVID-19 patients based on supportive therapy found the most use of antivirals, namely Favipiravir 97 (13.05%), use of antibiotics, namely ceftriaxone 31 (4.18%), use of vitamins 109% (72.97%), use of antihypertensive drugs 49 (6.61%), and based on symptomatic therapy according to frequent symptoms, 51 (6.88%) analgesics and antipyretics were found, 91 mucolytics (12.28%), 69 digestive disorders (9.31%).

References

E. Burhan et al., Pedoman Tatalaksana COVI19 EDISI 4, Ke4. Jakarta,Indonesia: Perhu=impunan Dokter Paru Indonesia (PDPI), 2022.

World Health Organization., “Coronavirus Disease 2019 (COVID-19),” WHO, 2020.

R. M. A. Satria, R. V. Tutupoho, and D. Chalidyanto, “Analisis Faktor Risiko Kematian dengan Penyakit Komorbid Covid-19,” J. Keperawatan Silampari, vol. 4, no. 1, pp. 48–55, 2020, doi: 10.31539/jks.v4i1.1587.

Kementrian Kesehatan Republik Indonesia, “Pemantauan Kasus COVID-19 di Indonesia.,” 2023. https://pusatkrisis.kemkes.go.id/covid-19-id/

D. K. Purworejo, “Statistik COVID-19 Kabupaten Purworejo.,” 2022.

H. Ariyani, S. Fitriani, and S. Rahmah, “Profil Penggunaan Obat pada Pasien COVID-19 di Rumah Sakit Umum Daerah Ulin Banjarmasin,” J. Pharmascience, vol. 8, no. 2, p. 133, 2021, doi: 10.20527/jps.v8i2.11144.

Keputusan Menteri Kesehatan Republik Indonesia, “Pedoman Pencegahan dan Pengendalian Corona Virus Disease 2019 (COVID-19),” MenKes/413/2020, vol. 2019, p. 207, 2020.

W. Wang, J. Tang, and F. Wei, “Updated understanding of the outbreak of 2019 novel coronavirus (2019-nCoV) in Wuhan, China,” J. Med. Virol., vol. 92, no. 4, pp. 441–447, 2020, doi: 10.1002/jmv.25689.

R. Khaerunnisa, N. A. Rumana, N. Yulia, and P. Fannya, “Gambaran Karakteristik Pasien Covid-19 di Rumah Sakit Mekar Sari Bekasi Tahun 2020-2021,” J. Manaj. Inf. Kesehat. Indones., vol. 10, no. 1, p. 72, 2022, doi: 10.33560/jmiki.v10i1.390.

U. Himatul, I. G. Noviyanty, and I. Ahmad, “Kajian Profil Pengobatan pada Pasien COVID-19 di Rumah Sakit X Kota Samarinda Tahun 2020,” Proceeding Mulawarman Pharm. Conf., no. April 2021, pp. 135–138, 2019, [Online]. Available: http://prosiding.farmasi.unmul.ac.id/index.php/mpc/article/view/416/399

Melviani and R. E. D. Yulianto, “Pola Penggunaan Suplemen Kesehatan Di Kalimantan Selatan Pada Masa Pandemi COVID-19 (Pattern of Use of Health Supplements in South Kalimantan During The Covid-19 Pandemic),” vol. 6, no. 1, 2022.

F. H. A. S. Erlina Burhan, Agus Dwi Susanto, Pedoman tatalaksana COVID-19 Edisi 3 Desember 2020. 2020. [Online]. Available: https://www.papdi.or.id/download/983-pedoman-tatalaksana-covid-19-edisi-3-desember-2020

K. Sanjaya, S. Paramita, and M. R. Khalidi, “Epidemiologi Karakteristik Pasien COVID-19 di Kutai Kartanegara pada Bulan Juli-Desember 2020,” J. Sains dan Kesehat., vol. 3, no. 6, pp. 876–884, 2021, doi: 10.25026/jsk.v3i6.604.

S. Adityo, R. C Martin, and W. P. Ceva, “Coronavirus Disease 2019: Tinjauan Literatur Terkini,” J. Penyakit Dlam Indones., vol. 7, no. 1, pp. 1 23, 2020, doi: 10.25104/transla.v22i2.1682.

M. Araban, M. Karimy, H. Koohestani, A. Montazeri, and D. Delaney, “Epidemiological and clinical characteristics of patients with COVID-19 in Islamic Republic of Iran,” East. Mediterr. Heal. J., vol. 28, no. 4, pp. 249–257, 2022, doi: 10.26719/emhj.22.008.

L. Marliana and L. Marliani, “Analisis Perbandingan Lama Rawat Inap Pasien Terdiagnosis Covid-19 Antara Pemberian Terapi Oseltamivir Dengan Favipiravir di RSUD R . Syamsudin S.H Sukabumi Periode Mei s.d Juli 2021,” J. Sos. dan Sains, vol. 1, no. November, pp. 1413–1422, 2021.

N. M. Maharianingsih, I. K. Sudirta, and N. P. A. Suryaningsih, “Karakteristik Pasien dan Penggunaan Obat Pada Pasien Covid-19 Derajat Sedang Hingga Berat,” Indones. J. Pharm. Educ., vol. 2, no. 2, pp. 101–109, 2022, doi: 10.37311/ijpe.v2i2.13958.

Muhammad Fakhry Ramadhan, Fetri Lestari, and Suwendar, “Profil Peresepan Terapi Obat Covid-19 pada Pasien Rawat Inap di Rumah Sakit Santosa Hospital Bandung Kopo Periode Juni-Juli 2021,” Bandung Conf. Ser. Pharm., vol. 2, no. 2, pp. 1109–1115, 2022, doi: 10.29313/bcsp.v2i2.4833.

Y. Wasiaturrahmah, A. M. Perdana Putra, N. Nahdha, and N. Rahmah, “Profil Penggunaan Obat Pada Pasien Covid-19 Di Salah Satu Rumah Sakit Di Banjarmasin,” J. Insa. Farm. Indones., vol. 5, no. 1, pp. 159–166, 2022, doi: 10.36387/jifi.v5i1.917.

J. sari Retno, Y. Rika, and H. Fauna, “Profil Penggunaan Obat Pada Pasien COVID-19 di Ruang Isolasi Rumah Sakit X Kabupaten Malang,” Malahayati Nurs. J., no. 265–4712, pp. 2870–2878, 2022.

A. K. Dewi and M. F. Sitorus, “Evaluasi Penggunaan Antibiotik Pasien Covid-19 Rsau Dr . M . Salamun Kota Bandung Antibiotic Usage Evaluation Of Covid-19 Patients Using Gyssens And Atc / Ddd Methods In Air Force Hospital Dr . M . SALAMUN IN BANDUNG CITY,” vol. 8, no. 2, pp. 713–722, 2023.

E. Suryanti, A. Rahem, and A. Purnamayanti, “Profil Penggunaan Obat Antivirus Covid-19 Di Rsud Dr. Murjani-Sampit,” J. Ilm. Ibnu Sina Ilmu Farm. dan Kesehat., vol. 7, no. 1, pp. 116–123, 2022, doi: 10.36387/jiis.v7i1.842.

M. Nasarah, H. Utami R, Y. Sumiyati, and A. Subhan, “Pengaruh Favipiravir dan Remdesivir Pada Pasien Covid-19 dengan Komorbid Penyakit Kardiovaskular & Hipertensi Terhadap Luaran Klinis Di RSUP Fatmawati Jakarta,” Poltekita J. Ilmu Kesehat., vol. 16, no. 3, pp. 296–308, 2022, doi: 10.33860/jik.v16i3.1613.

B. E. Rezkita, S. Irving, R. R. Pribadi, and M. Simadibrata, “Efektivitas Efikasi Pemberian Antivirus Favipiravir pada Pasien Covid-19: Evidence Based Case Report,” J. Kesehat. dan Kedokt., vol. 3, no. 2, pp. 100–107, 2022, doi: 10.24123/kesdok.v3i2.4786.

K. S. Sujana and M. Maulida, “Efektivitas N-Acetylsistein pada Pasien COVID-19,” Cermin Dunia Kedokt., vol. 48, no. 7, pp. 416–418, 2021, doi: 10.55175/cdk.v48i7.99.

K. J. Lin et al., “Gastrointestinal prophylaxis for COVID-19: an illustration of severe bias arising from inappropriate comparators in observational studies,” J. Clin. Epidemiol., vol. 151, pp. 45–52, 2022, doi: 10.1016/j.jclinepi.2022.07.009.

H. Luxenburger et al., “Treatment with proton pump inhibitors increases the risk of secondary infections and ARDS in hospitalized patients with COVID-19: coincidence or underestimated risk factor?,” J. Intern. Med., vol. 289, no. 1, pp. 121–124, 2021, doi: 10.1111/joim.13121.

L. Ramadani, N. Hidayat, and D. Fauziah, “Gambaran Penggunaan Analgetik pada Pasien Rawatan Intensif di RSUD Achmad Provinsi Riau Periode Januari-Desember 2015,” JOM, vol. 4, pp. 1–3, 2017.

D. E. Bimantara, “Peran Vitamin C dalam Pengobatan Covid-19,” Major. J., vol. 9, no. 1, pp. 1–4, 2020.

Kementerian Kesehatan Republik Indonesia, “Pedoman Pencegahan dan Pengendalian Serta Definisi Coronavirus Disease (COVID-19),” Germas, pp. 11–45, 2020, [Online]. Available: https://infeksiemerging.kemkes.go.id/download/REV-04_Pedoman_P2_COVID-19__27_Maret2020_TTD1.pdf [Diakses 11 Juni 2021].

S. R. Aisy, A. Rizal, and B. Y. Simanjuntak, “Vitamin C, Vitamin D Dan Imunitas Pasien Covid-19,” J. Nutr. Coll., vol. 12, no. 1, pp. 70–78, 2023, doi: 10.14710/jnc.v12i1.33167.

S. Hojyo and T. Fukada, “Roles of Zinc Signaling in the Immune System,” J. Immunol. Res., vol. 2016, 2016, doi: 10.1155/2016/6762343.

A. R. Scott, O. Stephanie, A. Chantelle, and A. Golo, “The Role Of Zink in Antiviral Immunity,” Am. Soc. Nutr., pp. 115, 2019, [Online]. Available: https://translate.google.com/translate?hl=id&sl=en&u=https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6628855/&prev=search&pto=aue